- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study Evaluating INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
This study is looking at a new medicine called INCB099280 for people with a type of skin cancer called advanced cutaneous squamous cell carcinoma. It's for patients whose cancer hasn't been treated with immunotherapy before and can't be cured by surgery or radiotherapy.
For: Treatment of immunotherapy-naive patients with previously untreated or recurrent locally advanced or metastatic cSCC not amenable to curative surgery and/or radiotherapySpain · Netherlands · Finland - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase I Study of INCB099280 in Combination With Ipilimumab in Participants With Selected Solid Tumors
This early-stage study is testing a new drug, INCB099280, combined with an existing cancer treatment, YERVOY, for solid tumours. Researchers want to see if this combination causes any serious side effects and how much of the new drug stays in the body. It's a first step to understand safety.
For: Solid tumorSweden · Norway · Slovakia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 STUDY EVALUATING INCB099280 IN PARTICIPANTS WITH SELECT SOLID TUMORS WHO ARE IMMUNE CHECKPOINT INHIBITOR–NAÏVE
This study is testing a new medicine called INCB099280 for people with certain advanced solid cancers that haven't been treated with immunotherapy before. Researchers want to see if the medicine shrinks tumors and how safe it is.
For: Recurrent or advanced/metastatic solid tumors who are immunotherapy naive and may or may not have been treated with prior therapy for their disease.Romania · Hungary · Greece - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1 Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
This study is looking at a new combination of medicines, INCB099280 and adagrasib, for adults with advanced solid cancers. These cancers have a specific gene change called 'KRASG12C'. We want to see how safe this combination is and if it helps control the cancer.
For: Advanced Solid Tumors Harboring a KRASG12C MutationItaly · France · Spain